131267Clinical version of the Physiomics Virtual TumourClosedFeasibility StudiesInnovate UKPersonalised medicine can be broken down into three key questions: which drugs do we give to a particular patient, how much and when? While many companies are seeking to address the first question, dosing and scheduling issues are poorly understood. Attrition rates in oncology remain high, part of the problem being that dosing and scheduling regimens are not optimised at the clinical trial stage. Physiomics has already developed the Virtual Tumour technology, which is used by our customers to optimise the dosing and scheduling of cancer drug candidates. However, the current version of the technology is only applicable to pre-clinical experiments. The company is now proposing a project to develop a clinical version of the Virtual Tumour. This would initially improve the success rate of cancer drugs proceeding through clinical trials. In the long run, if such a technology could be applied directly to patients, it would lead to real improvements in overall survival rates.